Contemporary advances in therapeutic portfolio of 2-Azetidinones
URN:NBN:sciencein.cbl.2020.v7.98
Published in Chemical Biology Letters
-
Rajneesh Kaur
Maharishi Markandeshwar (Deemed to be University)
-
Dr. (Mrs.) Raman Singh
Maharishi Markandeshwar (Deemed to be University)
-
Priyanka Ahlawat
Maharishi Markandeshwar (Deemed to be University)
-
Parul Kaushik
Maharishi Markandeshwar (Deemed to be University)
-
Kuldeep Singh
Maharishi Markandeshwar University
Keywords:
β-lactams, monobactam,
antimicrobial drug resistance, biological activity,
multi target drugs
Abstract
The heterocycle moieties form the site of reaction in many enzymes and co-enzymes and also act as an important pharmacophore in the pharmaceutical drug designs. 2-Azetidinones are the 2-carbonyl derivatives of azetidine, more commonly known as β-lactams. These structural entities occupied a central role in the vigil against bacterial infections over the past few decades. A subclass of these heterocyclic systems, monobactams or monocyclic β-lactam derivatives exhibits several biological activities including antibacterial, antifungal, antiprotozoal, anti-mycobacterial, anti-HIV, antiviral, antimalarial, antioxidant, apoptotic inhibitors, anti-inflammatory activity, anticancer activity, herbicidal activity, etc. Monobactams has resistant to the β-lactamase enzyme and could be a reasonable starting point for developing new drugs or inhibitors. In the present review, pharmacological activities of monocyclic β-lactam derivatives have been discussed with respect to current research in the structure-activity relationships in different therapeutic areas.
Cite as: Rajneesh, K., Singh, R., Ahlawat, P., Kaushik, P., & Singh, K. (2020). Contemporary advances in therapeutic portfolio of 2-Azetidinones. Chemical Biology Letters, 7(1), 13-26.
Retrieved full text from http://thesciencein.org/journal/index.php/cbl/article/view/98 and/or http://www.pubs.iscience.in/journal/index.php/cbl/article/view/987